arrow
P

Paul W. Armstrong

canadian vigour centre
H指数:118
被引数:8.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Rescue percutaneous coronary intervention in the pharmaco-invasive era of ST-elevation myocardial infarction: insights from the STREAM-2 trial

ST段抬高型心肌梗死药溶时代经皮冠状动脉介入治疗的补救措施:STREAM-2试验的启示

2025-12-010
PRE
Assessing Benefit in Heart Failure Patients with Reduced Ejection Fraction: Analysis of the VICTORIA Trial Using Novel Prognostic Risk Stratification

评估射血分数降低的心力衰竭患者的获益:使用新型预后风险分层对VICTORIA试验的分析

2025-08-280
OA
Pharmaco-Invasive Strategy With Half-Dose Tenecteplase in Patients With STEMI: Prespecified Pooled Analysis of Patients Aged ≥75 Years in STREAM-1 and 2

在STEMI患者中使用半剂量tenectepase的药物侵入性策略: STREAM-1和2中年龄 ≥ 75岁的患者的预设汇总分析

2024-12-010
PRE
Half-Dose Tenecteplase or Primary Percutaneous Coronary Intervention in Older Patients With ST-Elevation Myocardial Infarction: STREAM-2 1-Year Mortality Follow-Up
2024-10-010
PRE
Proteomics Identify Clinical Phenotypes and Predict Functional Outcomes in Heart Failure With Preserved Ejection Fraction: Insights From VITALITY-HFpEF

蛋白质组学鉴定临床表型并预测射血分数保留的心力衰竭的功能结果: 来自活力-HFpEF的见解

2024-09-010
PRE
Biomarker profiles associated with reverse ventricular remodelling in patients with heart failure and a reduced ejection fraction: Insights from the echocardiographic substudy of the VICTORIA trial

与心力衰竭和射血分数降低患者的逆向心室重塑相关的生物标志物谱: 来自VICTORIA试验的超声心动图子研究的见解

2024-07-301
OA
Relationship between baseline electrocardiographic measurements and outcomes in patients with high-risk heart failure: insights from the VerICiguaT Global Study in Subjects with Heart Failure with Reduced Ejection Fraction (VICTORIA) trial
2023-09-103
OA